Urology @ Massachusetts General Hospital. Urologic oncology fellowship @ MD Anderson Cancer Center. Currently @ Cleveland Clinic Florida. Urologic Oncology
Joined May 2019
- Tweets475
- Following251
- Followers449
- Likes1.4K
Alberto Pieretti retweeted
PROTEUS Substudy: Periop Apa + ADT with RP+PLND vs RP+PLND in HR PCa @urotoday #ESMO26
Periop APA + ADT (+ RP+PLND; n= 102) vs RP+PLND alone (n=306)
🚨EFS: HR 0.38, 95% CI 0.26–0.55
🚨MFS: HR 0.49, 95% CI 0.26–0.90
🚨TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
🚨All Gr Hot Flush: 64% vs 0.7%
Alberto Pieretti retweeted
Great day learning the fundamentals of robotic skills here in FL. Thanks to @IntuitiveSurg for setting up this awesome sim lab for our trainees!
Alberto Pieretti retweeted
Long-term oncologic outcomes of patients with grade group 1 #ProstateCancer and pT3a disease on final pathology.
In 40 men with centrally confirmed Grade Group 1 prostate cancer and pT3a disease, none developed metastases or died of prostate cancer. Adverse histology, not stage alone, drives clinically meaningful risk. #AuthorCommentary on UroToday > bit.ly/4hJBXDF @JaneNguyen44 @ZSchwen @MWatfa26 @CleClinicUro @pcan_journal
Alberto Pieretti retweeted
Calling all urology applicants!! 📢
We invite you to join us the Cleveland Clinic Florida Virtual Open House.
Come and learn about all the exiting things happening at our growing program.
Date: Tuesday September 15, 2026
Time: 5:00 to 6:00 PM EST
events.teams.microsoft.com/e…
It was a pleasure to represent @AmerUrological at @SauUrologia. Great meeting. Buenos Aires is an amazing city. Looking forward to continuing to collaborate in the future. @BernardoNor9 @CleClinicUro_FL @CleClinicUro @drjkaouk @chadritchmd
Alberto Pieretti retweeted
Congrats to @DrFAbdollah and team on genuine 10-yr follow-up of a real RCT — rare and valuable, though at n=60/arm, randomization for continence outcomes can't fully protect against chance baseline imbalance in pathology. However, reporting outcomes honestly deserves real credit.
Worth reading past the headline:
• Post hoc analysis — trial was designed/powered for continence, not oncologic outcomes
• Surgeons were highly experienced anteriorly but early in their RS learning curve
• pT3 disease 45% (RS) vs 23% (anterior); PSM 25% vs 13%
• Only 9 patients remained at risk at the 10-yr mark
• Authors fairly call it "hypothesis-generating"
Good data, not a verdict. Bigger, prospective, contemporary RCTs will tell us more.
Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort by Alfonso Santangelo ...Firas Abdollah et al
buff.ly/OZUURYD
Thank you to all the authors for trusting EUO to publish your work!
@santangelo_alfo
@DrFAbdollah
@pr.morgan.roupret
@ric_campi89
@laura.marandino
@jteoh_hk
@davdandrea
@renu.eapen
@uroweb
@gu_cast_podcast
@oncoalert
@elsevier_oncology
@elsevier_connect
Alberto Pieretti retweeted
We’re a growing program with big ambitions and exciting things ahead. 🚀
New people. New ideas. New opportunities to advance urologic care across Florida ☀️
We’re just getting started. 😎🌴
newsroom.clevelandclinic.org…
Alberto Pieretti retweeted
📢@CleClinicUro_FL is growing! We are seeking a BE/BC urologist with fellowship training in sexual medicine, andrology and infertility. Exciting opportunity to join a high volume, world class team, and shape the training & research program in FL☀️🌴!
Alberto Pieretti retweeted
Late to the game on X, but not to urology.
Meet Cleveland Clinic Florida Urology. Following in the footsteps of our big sibling @CleClinicUro to expand education, innovation, research and first class patient care across the sunshine state ☀️ 🌴
Alberto Pieretti retweeted
Big week for #prostatecancer news @JAMA_current!
First @grace_syl for PROFOUND-VET: use of #activesurveillance is now 93% for low-risk disease and 62% for favorable intermediate. Huge news and proof that @VeteransHealth is leading the way in this area.
dx.doi.org/10.1001/jama.2026…
For those planning a family vacation trip: Siesta Key is highly recommended!!! Florida has amazing places!
Alberto Pieretti retweeted
New in @JAMANetworkOpen: @SWOG S1600, a multicenter phase 3 RCT, found no reduction in 30- or 90-day complications w/ specialized immunonutrition vs standard nutrition after cystectomy. Exploratory DFS/OS favored immunonutrition. #BladderCancer
@JhamiltonReeves @DrJoeUnger @JMHolzbeierlein @FoxChaseCancer @BCM_Urology @JanetKukreja @eugenekanglee @URMCUrology @DrDawnHershman @fischmd @lynnhenrymd jamanetwork.com/journals/jam…
Alberto Pieretti retweeted
pCR at cystectomy have reached levels not seen before after neoadjuvant therapy and are increasingly being proposed as a surrogate endpoint for clinical trials, but ... does improving pCR reliably predict improving overall survival?
In our collaborative study in @EurUrolOncol we analyzed 12 prospective neoadjuvant trials (3,119 patients) using a formal two-step trial-level surrogacy framework. @Pietro9609 @AndreaNecchi @drenriquegrande @BenjaminPradere @DrShariat @AlisonBirtle @OncoBellmunt @MRoupret
@ThoSeisen @laconss @slusarczyk_alek @UroMoschini
🧵
Alberto Pieretti retweeted
Another day another 📝 by our super team
🧬 New @AnnSurgOncol if one has preop ctDNA before radical Cystectomy ( post Turbt NOT turned -with chemo) can it flag who’s truly node-negative at surgery .?? Def 👌What we found:
• NPV 96% | Sens 86% | Spec 79% ( → 1 false-neg (sampled during NAC)
• Simulated LND omission ‼️spares LND in 27/40, misses 1 limited pN1
• Pooled w/ Ben-David (n=149): NPV 92%
Of course LND stays standard. But ctDNA– as a low-risk signal is worth a prospective trial. 🔬 don’t need super extended LND with persistently negative ctDNA @NateraGenetics
link.springer.com/article/10…
Alberto Pieretti retweeted
Alberto Pieretti retweeted
📢 Calling all rising BE uro chiefs 🚨excellent 1 year opportunity to fine tune your robotics/MIS/onc skills here @CleveClinicFL in 2027! ✅High volume program ✅collegial & talented group ✅ attending/instructor privileges ✅ DaVinci SP & multiport ✅ ☀️🌊 location!! DM me
Alberto Pieretti retweeted
Thrilled to share #PRIMARY2 Trial Results. This is the first randomised trial to show that adding [⁶⁸Ga]Ga-PSMA-11 PET-CT to MRI can safely halve the number of men needing a prostate biopsy.
Hot off the press in @TheLancetOncol 🎉
In 660 men across Australian sites with PI-RADS 2-3 but high clinical risk, PSMA-PET:
- Avoided biopsy in nearly half (49%)
- Was non-inferior for detecting clinically significant cancer (12% vs 16%)
- Halved the overdiagnosis of insignificant cancer (32% to 14%)
Fewer biopsies, less overdiagnosis, whilst not missing clinically significant prostate cancer: a real step forward for the diagnostic pathway.
Enormous congratulations to @ButeauJames @PeterMacCC , who led this as the centrepiece of his PhD and presented it as a plenary at #EAU26 in London. And to my brilliant co-lead @drlouiseemmett - this was a true partnership across our two centres.
Thank you to the UROLOGISTS @DrDanielMoon @declangmurphy (& many others), nuclear medicine physicians, technologists, radiopharmaceutical scientists across every site, and to @AnnetteVDHeyden and the @pros_tic who held it all together.
We are grateful to our funders: @PCF_Science, @nhmrc, St Vincent's Curran Foundation, Peter MacCallum Cancer Foundation, and @ANZUPtrials
Most of all, thank you to the 660 men who took part.
Open Access article: thelancet.com/journals/lanon…
